A Phase 2 Feasibility Study of Sotrastaurin for Relapsed and Refractory CLL/SLL/PLL/RT
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Sotrastaurin (Primary)
- Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Apr 2017 Planned End Date changed from 12 Mar 2015 to 13 Mar 2015.
- 03 Apr 2017 Planned primary completion date changed from 1 May 2017 to 13 Mar 2015.